T1	PROC 46 64	Terapia secuencial
T2	CHEM 69 79	tacrolimus
#1	AnnotatorNotes T2	C0085149; tacrolimus; Organic Chemical · Pharmacologic Substance
T3	CHEM 82 91	rituximab
#2	AnnotatorNotes T3	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	ANAT 106 116	membranosa
#3	AnnotatorNotes T4	C0025255; Tissue membrane; Tissue | C0596901; Membrane; Cell Component
T5	PROC 148 204	Ensayo multicéntrico, aleatorizado, controlado y abierto
T6	PROC 210 229	evaluar la eficacia
#4	AnnotatorNotes T6	C1707887; Efficacy Study; Research Activity
T7	PROC 234 256	tratamiento secuencial
#5	AnnotatorNotes T7	C1519252; Sequential Treatment; Therapeutic or Preventive Procedure
T8	CHEM 261 271	tacrolimus
#6	AnnotatorNotes T8	C0085149; tacrolimus; Organic Chemical · Pharmacologic Substance
T9	CHEM 272 281	rituximab
#7	AnnotatorNotes T9	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 289 299	esteroides
#8	AnnotatorNotes T10	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T11	CHEM 304 318	ciclofosfamida
#9	AnnotatorNotes T11	C0010583; cyclophosphamide; Organic Chemical · Pharmacologic Substance
T12	DISO 336 357	nefropatía membranosa
#10	AnnotatorNotes T12	C0017665; Membranous glomerulonephritis; Disease or Syndrome
T13	ANAT 402 412	MEMBRANOSA
#11	AnnotatorNotes T13	C0025255; Tissue membrane; Tissue | C0596901; Membrane; Cell Component
T14	DISO 439 460	Nefropatía membranosa
#12	AnnotatorNotes T14	C0017665; Membranous glomerulonephritis; Disease or Syndrome
T15	DISO 95 116	nefropatía membranosa
#13	AnnotatorNotes T15	C0017665; Membranous glomerulonephritis; Disease or Syndrome
T16	ANAT 347 357	membranosa
#14	AnnotatorNotes T16	C0025255; Tissue membrane; Tissue | C0596901; Membrane; Cell Component
T17	ANAT 450 460	membranosa
#15	AnnotatorNotes T17	C0025255; Tissue membrane; Tissue | C0596901; Membrane; Cell Component
T18	DISO 391 412	NEFROPATIA MEMBRANOSA
#16	AnnotatorNotes T18	C0017665; Membranous glomerulonephritis; Disease or Syndrome
T19	Date 13 17	2013
T20	LIVB 322 331	pacientes
#17	AnnotatorNotes T20	C0030705; Patients; Patient or Disabled Group
#18	AnnotatorNotes T5	C1096776; Multicenter Study; Research Activity + C0206035; Controlled Clinical Trials, Randomized; Research Activity + C1709323; Open Label Study; Research Activity
T21	LIVB 506 515	pacientes
#21	AnnotatorNotes T21	C0030705; Patients; Patient or Disabled Group
T22	LIVB 622 630	paciente
#22	AnnotatorNotes T22	C0030705; Patients; Patient or Disabled Group
T24	PROC 749 773	consentimiento informado
#24	AnnotatorNotes T24	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T25	PROC 922 931	selección
#25	AnnotatorNotes T25	C0242802; Patient Selection; Research Activity
T26	PROC 948 957	protocolo
#26	AnnotatorNotes T26	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T27	PROC 991 1005	procedimientos
#27	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T28	PROC 1070 1077	estudio
#28	AnnotatorNotes T28	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T29	DISO 1106 1108	MN
#29	AnnotatorNotes T29	C0017665; Membranous glomerulonephritis; Disease or Syndrome
T30	LIVB 1175 1184	pacientes
#30	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	DISO 1189 1196	recaída
#31	AnnotatorNotes T31	C2825055; Recurrence (disease attribute); Pathologic Function
T32	DISO 1201 1219	síndrome nefrótico
#32	AnnotatorNotes T32	C0027726; Nephrotic Syndrome; Disease or Syndrome
T33	PROC 1133 1140	biopsia
#33	AnnotatorNotes T33	C0005558; Biopsy; Diagnostic Procedure
T34	Observation 1234 1242	remisión
#34	AnnotatorNotes T34	C0544452; Disease remission; Finding
T36	PROC 1276 1291	inmunosupresión
#36	AnnotatorNotes T36	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive Procedure
T39	PROC 1329 1342	biopsia renal
#39	AnnotatorNotes T39	C0194073; Kidney biopsy; Diagnostic Procedure
T40	Quantifier_or_Qualifier 1323 1328	nueva
#40	AnnotatorNotes T40	C0205314; New; Qualitative Concept
T41	ANAT 1337 1342	renal
#41	AnnotatorNotes T41	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T42	DISO 1455 1466	Proteinuria
#42	AnnotatorNotes T42	C0033687; Proteinuria; Finding
T45	DISO 1476 1485	nefrótico
#45	AnnotatorNotes T45	C0027720; Nephrosis; Disease or Syndrome
T46	DISO 1548 1563	hipoalbuminemia
#46	AnnotatorNotes T46	C0239981; Hypoalbuminemia; Disease or Syndrome
T47	PROC 1639 1650	Tratamiento
#47	AnnotatorNotes T47	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T48	PROC 1734 1751	presión sanguínea
#48	AnnotatorNotes T48	C0005824; Blood pressure determination; Health Care Activity
T51	ANAT 1742 1751	sanguínea
#51	AnnotatorNotes T51	C0005767; Blood; Body Substance
T52	Quantifier_or_Qualifier 1752 1762	controlada
T53	PROC 1823 1841	Prueba de embarazo
#53	AnnotatorNotes T53	C0032976; Pregnancy Tests; Diagnostic Procedure
T54	PHYS 1833 1841	embarazo
#54	AnnotatorNotes T54	C0032961; Pregnancy; Organism Function
T56	ANAT 1845 1850	orina
#56	AnnotatorNotes T56	C0042036; Urine; Body Substance
T57	LIVB 1865 1896	mujeres potencialmente fértiles
#57	AnnotatorNotes T57	C4324275; Woman of childbearing potential; Population Group
T59	PROC 1925 1936	Diagnostico
#59	AnnotatorNotes T59	C0011900; Diagnosis; Diagnostic Procedure
T60	DISO 1962 1983	nefropatía membranosa
#60	AnnotatorNotes T60	C0017665; Membranous glomerulonephritis; Disease or Syndrome
T61	ANAT 1973 1983	membranosa
#61	AnnotatorNotes T61	C0025255; Tissue membrane; Tissue
T62	PROC 1985 1996	diagnóstico
#62	AnnotatorNotes T62	C0011900; Diagnosis; Diagnostic Procedure
T63	DISO 2000 2028	diabetes mellitus tipo 1 o 2
#63	AnnotatorNotes T63	C0011854; Diabetes Mellitus, Insulin-Dependent; Disease or Syndrome | C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T64	DISO 2042 2048	cáncer
#64	AnnotatorNotes T64	C0006826; Malignant Neoplasms; Neoplastic Process
T65	DISO 2051 2073	infecciones sistémicas
#65	AnnotatorNotes T65	C0243026; Sepsis; Disease or Syndrome
T66	LIVB 2095 2102	virales
#66	AnnotatorNotes T66	C0042776; Virus; Virus
T67	DISO 2104 2111	malaria
#67	AnnotatorNotes T67	C0024530; Malaria; Disease or Syndrome
T68	DISO 2113 2128	hepatitis B y C
#68	AnnotatorNotes T68	C0019163; Hepatitis B; Disease or Syndrome + C0019196; Hepatitis C; Disease or Syndrome
T69	DISO 2130 2135	lepra
#69	AnnotatorNotes T69	C0023343; Leprosy; Disease or Syndrome
T70	DISO 2138 2145	sífilis
#70	AnnotatorNotes T70	C0039128; Syphilis; Disease or Syndrome
T71	DISO 2148 2183	enfermedades autoinmunes sistémicas
#71	AnnotatorNotes T71	C2895206; Systemic autoimmune disease; Disease or Syndrome
T72	DISO 2189 2216	lupus eritematoso sistémico
#72	AnnotatorNotes T72	C0024141; Lupus Erythematosus, Systemic; Disease or Syndrome
T73	DISO 2224 2235	amiloidosis
#73	AnnotatorNotes T73	C0002726; Amyloidosis; Disease or Syndrome | C0011560; Amyloid deposition; Pathologic Function
T74	DISO 2253 2276	enfermedad inflamatoria
#74	AnnotatorNotes T74	C1290884; Inflammatory disorder; Disease or Syndrome
T76	Quantifier_or_Qualifier 2277 2282	aguda
#76	AnnotatorNotes T76	C0439557; Acute phase; Temporal Concept
T77	DISO 2296 2313	Infección por VIH
#77	AnnotatorNotes T77	C0019693; HIV Infections; Disease or Syndrome
T78	LIVB 2310 2313	VIH
#78	AnnotatorNotes T78	C0019682; HIV; Virus
T79	DISO 2317 2336	Enfermedad hepática
#79	AnnotatorNotes T79	C0023895; Liver diseases; Disease or Syndrome
T80	ANAT 2328 2336	hepática
#80	AnnotatorNotes T80	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T83	PROC 2355 2358	AST
#83	AnnotatorNotes T83	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T85	PROC 2361 2364	ALT
#85	AnnotatorNotes T85	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T87	PROC 2410 2427	bilirrubina total
#87	AnnotatorNotes T87	C0201913; Bilirubin, total measurement; Laboratory Procedure
T88	CHEM 2410 2421	bilirrubina
#88	AnnotatorNotes T88	C0005437; Bilirubin; Biologically Active Substance · Organic Chemical
T89	LIVB 2463 2472	Pacientes
#89	AnnotatorNotes T89	C0030705; Patients; Patient or Disabled Group
T91	PROC 2530 2554	estudio de investigación
#91	AnnotatorNotes T91	C0681814; research study; Research Activity
T92	PROC 2593 2604	tratamiento
#92	AnnotatorNotes T92	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T93	CHEM 2614 2621	fármaco
#93	AnnotatorNotes T93	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T94	PROC 2624 2653	intervención de investigación
#94	AnnotatorNotes T94	C0949266; Therapies, Investigational; Therapeutic or Preventive Procedure (?)
T96	PROC 2687 2694	estudio
#96	AnnotatorNotes T96	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T97	DISO 2699 2716	Hipersensibilidad
#97	AnnotatorNotes T97	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T98	DISO 2718 2725	alergia
#98	AnnotatorNotes T98	C1527304; Allergic Reaction; Pathologic Function
T101	DISO 2742 2763	reacción inmunogénica
T102	CHEM 2790 2799	rituximab
#102	AnnotatorNotes T102	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T103	CHEM 2801 2813	ciclosporina
#103	AnnotatorNotes T103	C0010592; cyclosporine; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T104	CHEM 2815 2825	tacrolimus
#104	AnnotatorNotes T104	C0085149; tacrolimus; Organic Chemical · Pharmacologic Substance
T105	CHEM 2827 2844	corticoesteroides
#105	AnnotatorNotes T105	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T106	CHEM 2846 2849	CYC
T107	CHEM 2870 2882	ingredientes
#107	AnnotatorNotes T107	C1550600; Ingredient; Chemical Viewed Functionally
T108	CHEM 2900 2911	excipientes
#108	AnnotatorNotes T108	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T109	CHEM 2942 2949	fármaco
#109	AnnotatorNotes T109	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T111	CHEM 2990 3020	inhibidores de la calcineurina
#111	AnnotatorNotes T111	C1562036; Calcineurin inhibitor; Pharmacologic Substance
T112	CHEM 3022 3046	anticuerpos monoclonales
#112	AnnotatorNotes T112	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T114	CHEM 3061 3080	agentes alquilantes
#114	AnnotatorNotes T114	C0002073; Alkylating Agents; Hazardous or Poisonous Substance · Pharmacologic Substance
T115	PROC 3085 3096	Tratamiento
#115	AnnotatorNotes T115	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T116	CHEM 3108 3125	corticoesteroides
#116	AnnotatorNotes T116	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T117	CHEM 3143 3165	fármaco inmunosupresor
#117	AnnotatorNotes T117	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T118	PROC 3229 3240	Tratamiento
#118	AnnotatorNotes T118	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T119	CHEM 3252 3261	rituximab
#119	AnnotatorNotes T119	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T120	CHEM 3269 3285	agente biológico
#120	AnnotatorNotes T120	C0005515; Biological Factors; Biologically Active Substance
T121	LIVB 3345 3354	Pacientes
#121	AnnotatorNotes T121	C0030705; Patients; Patient or Disabled Group
T122	CHEM 3389 3405	inmunosupresores
#122	AnnotatorNotes T122	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T123	LIVB 3417 3424	Mujeres
#123	AnnotatorNotes T123	C0043210; Woman; Population Group | C0242665; wife; Family Group
T124	PROC 3429 3447	prueba de embarazo
#124	AnnotatorNotes T124	C0032976; Pregnancy Tests; Diagnostic Procedure
T125	PHYS 3439 3447	embarazo
#125	AnnotatorNotes T125	C0032961; Pregnancy; Organism Function
T126	PHYS 3470 3490	período de lactancia
#126	AnnotatorNotes T126	C0022925; Lactation; Organ or Tissue Function
T127	LIVB 3518 3525	Mujeres
#127	AnnotatorNotes T127	C0043210; Woman; Population Group | C0242665; wife; Family Group
T128	PROC 3550 3573	metodos anticonceptivos
#128	AnnotatorNotes T128	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T129	CHEM 3558 3573	anticonceptivos
#129	AnnotatorNotes T129	C0009871; Contraceptive Agents; Pharmacologic Substance
T130	PROC 3604 3611	estudio
#130	AnnotatorNotes T130	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity | C2603343; Study; Research Activity
T131	DISO 3615 3626	Incapacidad
#131	AnnotatorNotes T131	C0231172; handicapping condition; Finding
T132	LIVB 3648 3657	individuo
#132	AnnotatorNotes T132	C0027361; Persons; Population Group
T133	LIVB 3666 3685	representante legal
#133	AnnotatorNotes T133	C4288823; Legal Representative for the Study; Human
T134	PROC 3695 3731	consentimiento informado por escrito
#134	AnnotatorNotes T134	C0811741; Obtain informed written consent; Health Care Activity
T135	DISO 3750 3766	condición médica
#135	AnnotatorNotes T135	C4745084; Medical Condition; Finding
T136	Quantifier_or_Qualifier 3767 3776	inestable
T137	Quantifier_or_Qualifier 3781 3791	controlada
T138	Observation 3818 3851	hallazgo de laboratorio relevante
#138	AnnotatorNotes T138	C3648370; laboratory tests nonspecific abnormal findings; Finding (?)
T139	LIVB 3879 3891	investigador
#139	AnnotatorNotes T139	C0035173; Research Personnel; Professional or Occupational Group
T140	LIVB 3969 3977	paciente
#140	AnnotatorNotes T140	C0030705; Patients; Patient or Disabled Group
T142	DISO 4001 4012	dependencia
#142	AnnotatorNotes T142	C2919052; Alcohol or other drugs dependence; Mental or Behavioral Dysfunction
T143	CHEM 4022 4028	drogas
#143	AnnotatorNotes T143	C0813966; addictive drug; Hazardous or Poisonous Substance
T144	Food 4031 4038	alcohol
#144	AnnotatorNotes T144	C0001967; Alcoholic Beverages; Food
T145	LIVB 4059 4071	investigador
#145	AnnotatorNotes T145	C0035173; Research Personnel; Professional or Occupational Group
T146	Observation 4107 4150	adherencia a los requerimientos del estudio
#146	AnnotatorNotes T146	C0001511; Tissue Adhesions; Pathologic Function
R1	Location_of Arg1:T4 Arg2:T15	
R2	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T150	
R3	Location_of Arg1:T16 Arg2:T12	
R4	Location_of Arg1:T13 Arg2:T18	
R5	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T149
R6	Location_of Arg1:T17 Arg2:T14	
R7	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T148	
R8	Combined_with Arg1:T8 Arg2:T9	
R9	Used_for Arg1:T8 Arg2:T7	
R10	Combined_with Arg1:T10 Arg2:T11	
R11	Used_for Arg1:T10 Arg2:T7	
R12	Experiences Arg1:T20 Arg2:T7	
R13	Experiences Arg1:T20 Arg2:T12
R14	Used_for Arg1:T2 Arg2:T1	
R15	Used_for Arg1:T3 Arg2:T1	
T148	Quantifier_or_Qualifier 461 469	primaria
#148	AnnotatorNotes T148	C0205225; Primary; Qualitative Concept
T149	Quantifier_or_Qualifier 358 366	primaria
#149	AnnotatorNotes T149	C0205225; Primary; Qualitative Concept
T150	Quantifier_or_Qualifier 117 125	primaria
#150	AnnotatorNotes T150	C0205225; Primary; Qualitative Concept
#19	AnnotatorNotes T1	C1519252; Sequential Treatment; Therapeutic or Preventive Procedure
T151	Observation 522 545	dispuestos a participar
R16	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T151	
T152	PHYS 564 568	leer
#20	AnnotatorNotes T152	C2372013; Reading; Mental Process
R17	Experiences Arg1:T21 Arg2:T152	
T153	PHYS 571 581	comprender
#151	AnnotatorNotes T153	C0162340; Comprehension; Mental Process
R18	Experiences Arg1:T21 Arg2:T153	
T154	CONC 599 618	hoja de información
R19	Overlap Arg1:T153 Arg2:T154	
R20	Overlap Arg1:T152 Arg2:T154	
T155	PROC 640 654	consentimiento
#152	AnnotatorNotes T155	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
R21	Experiences Arg1:T21 Arg2:T155	
R22	Experiences Arg1:T22 Arg2:T155	
R23	Experiences Arg1:T22 Arg2:T153	
R24	Experiences Arg1:T22 Arg2:T152	
R25	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T151	
T156	Observation 663 690	participación en el estudio
#153	AnnotatorNotes T156	C1278516; Patient participation status; Finding (?)
R26	Before Arg1:T155 Arg2:T156	
R27	Before Arg1:T25 Arg2:T156	
R29	Before Arg1:T24 Arg2:T156	
R28	Experiences Arg1:T22 Arg2:T25	
R30	Experiences Arg1:T21 Arg2:T25	
T23	PHYS 976 986	comprender
#23	AnnotatorNotes T23	C0162340; Comprehension; Mental Process
R31	Overlap Arg1:T23 Arg2:T27	
T157	Observation 1020 1031;987 1005	cumplir con los procedimientos
#154	AnnotatorNotes T157	C0582783; Ability to comply with treatment; Finding (?)
R32	Overlap Arg1:T23 Arg2:T28	
R33	Overlap Arg1:T157 Arg2:T28	
T158	Age 1086 1102	mayor de 18 años
T159	Quantifier_or_Qualifier 1109 1117	primaria
#155	AnnotatorNotes T159	C0205225; Primary; Qualitative Concept
R34	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T159	
T160	Duration 1151 1169	los últimos 2 años
R35	Overlap Arg1:T29 Arg2:T160	
R36	Overlap Arg1:T33 Arg2:T160	
R37	Before Arg1:T32 Arg2:T31	
R38	Experiences Arg1:T30 Arg2:T31	
R39	Experiences Arg1:T30 Arg2:T32	
R40	After Arg1:T31 Arg2:T34	
R41	Experiences Arg1:T30 Arg2:T34	
T161	Quantifier_or_Qualifier 1250 1260	espontánea
#156	AnnotatorNotes T161	C0205359; Spontaneous; Functional Concept
R42	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T161	
R43	Experiences Arg1:T30 Arg2:T36	
R44	Causes Arg1:T36 Arg2:T34	
T35	Neg_cue 1315 1318	sin
A1	Assertion T40 Negated
R45	Negation Arg1:T35 Arg2:T40	
A2	Assertion T39 Negated
R46	Negation Arg1:T35 Arg2:T39	
R47	Location_of Arg1:T41 Arg2:T39	
R48	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T40	
R49	Experiences Arg1:T30 Arg2:T39	
T37	Observation 1360 1415	reúnen todos los demás criterios de inclusión/exclusión
#35	AnnotatorNotes T37	C4329786; Eligibility Criteria Met By Subject; Finding
T38	Result_or_Value 1432 1451	>= 45 ml/min/1.73m2
T162	PROC 1419 1431	GFR estimada
#37	AnnotatorNotes T162	C0017654; Glomerular Filtration Rate; Diagnostic Procedure
R50	Has_Result_or_Value Arg1:T162 Arg2:T38	
T163	Neg_cue 1851 1859	negativa
A3	Assertion T54 Negated
R51	Negation Arg1:T163 Arg2:T54	
R52	Location_of Arg1:T56 Arg2:T53	
R53	Experiences Arg1:T57 Arg2:T53	
T55	Spec_cue 1873 1887	potencialmente
T164	Quantifier_or_Qualifier 1888 1896	fértiles
A4	Assertion T164 Speculated
R54	Speculation Arg1:T55 Arg2:T164	
R55	Has_Quantifier_or_Qualifier Arg1:T57 Arg2:T164	
R56	Location_of Arg1:T61 Arg2:T60	
R57	Causes Arg1:T66 Arg2:T65	
T58	DISO 2218 2221	LES
#38	AnnotatorNotes T58	C0024141; Lupus Erythematosus, Systemic; Disease or Syndrome
R58	Causes Arg1:T78 Arg2:T77	
R59	Causes Arg1:T63 Arg2:T60	
R60	Causes Arg1:T64 Arg2:T60	
T165	DISO 2030 2040	malignidad
#55	AnnotatorNotes T165	C0006826; Malignant Neoplasms; Neoplastic Process
R61	Causes Arg1:T165 Arg2:T60	
R62	Causes Arg1:T65 Arg2:T60	
R63	Causes Arg1:T67 Arg2:T60	
R64	Causes Arg1:T68 Arg2:T60	
R65	Causes Arg1:T69 Arg2:T60	
R66	Causes Arg1:T70 Arg2:T60	
R67	Causes Arg1:T71 Arg2:T60	
R68	Causes Arg1:T72 Arg2:T60	
R69	Causes Arg1:T58 Arg2:T60	
R70	Causes Arg1:T73 Arg2:T60	
T166	Duration 2285 2292	crónica
#58	AnnotatorNotes T166	C0205191; chronic; Temporal Concept
R71	Has_Quantifier_or_Qualifier Arg1:T74 Arg2:T76	
R72	Has_Duration_or_Interval Arg1:T74 Arg2:T166	
R73	Causes Arg1:T74 Arg2:T60	
R74	Location_of Arg1:T80 Arg2:T79	
T75	Result_or_Value 2365 2407	> 2.5 veces por encima del límite superior
R75	Has_Result_or_Value Arg1:T85 Arg2:T75	
R76	Has_Result_or_Value Arg1:T83 Arg2:T75	
T81	Result_or_Value 2428 2458	> 1.5 veces el límite superior
R77	Has_Result_or_Value Arg1:T87 Arg2:T81	
T82	Quantifier_or_Qualifier 2337 2353	moderada o grave
#75	AnnotatorNotes T82	C1299393; Moderate to severe; Qualitative Concept
R78	Has_Quantifier_or_Qualifier Arg1:T79 Arg2:T82	
T84	Observation 2483 2521	participando en cualquier otro estudio
#81	AnnotatorNotes T84	C1278516; Patient participation status; Finding
R79	Used_for Arg1:T93 Arg2:T92	
R80	Experiences Arg1:T89 Arg2:T92	
T86	Duration 2666 2676	primer mes
R81	Has_Duration_or_Interval Arg1:T93 Arg2:T86	
R82	Before Arg1:T92 Arg2:T96	
R83	Before Arg1:T94 Arg2:T96	
R84	Has_Duration_or_Interval Arg1:T94 Arg2:T86	
R85	Experiences Arg1:T89 Arg2:T94	
T90	Spec_cue 2776 2786	sospechada
A5	Status T101 History_of
A6	Assertion T101 Speculated
R86	Speculation Arg1:T90 Arg2:T101	
R87	Causes Arg1:T102 Arg2:T97	
R88	Causes Arg1:T102 Arg2:T98	
R89	Causes Arg1:T103 Arg2:T101	
R90	Causes Arg1:T102 Arg2:T101	
R91	Causes Arg1:T103 Arg2:T98	
R92	Causes Arg1:T103 Arg2:T97	
R93	Causes Arg1:T104 Arg2:T97	
R94	Causes Arg1:T104 Arg2:T98	
R95	Causes Arg1:T104 Arg2:T101	
R96	Causes Arg1:T105 Arg2:T97	
R97	Causes Arg1:T105 Arg2:T98	
R98	Causes Arg1:T105 Arg2:T101	
R99	Causes Arg1:T109 Arg2:T97	
R100	Causes Arg1:T109 Arg2:T98	
R101	Causes Arg1:T109 Arg2:T101	
R102	Causes Arg1:T114 Arg2:T97	
R103	Causes Arg1:T114 Arg2:T98	
R104	Causes Arg1:T114 Arg2:T101	
R105	Causes Arg1:T111 Arg2:T97	
R106	Causes Arg1:T111 Arg2:T98	
R107	Causes Arg1:T111 Arg2:T101	
R108	Causes Arg1:T112 Arg2:T97	
R109	Causes Arg1:T112 Arg2:T98	
R110	Causes Arg1:T112 Arg2:T101	
R111	Causes Arg1:T106 Arg2:T101	
R112	Causes Arg1:T106 Arg2:T98	
R113	Causes Arg1:T106 Arg2:T97	
A7	Status T115 History_of
A8	Status T116 History_of
R114	Used_for Arg1:T116 Arg2:T115	
A9	Status T117 History_of
R115	Used_for Arg1:T117 Arg2:T115	
T95	Duration 3169 3183	los seis meses
T99	PROC 3206 3215	selección
#82	AnnotatorNotes T99	C0242802; Patient Selection; Research Activity
R116	Has_Duration_or_Interval Arg1:T116 Arg2:T95	
R117	Has_Duration_or_Interval Arg1:T117 Arg2:T95	
R118	Before Arg1:T115 Arg2:T99	
T100	CONC 3216 3225	inclusión
#84	AnnotatorNotes T100	C1512693; Inclusion; Qualitative Concept
R119	Before Arg1:T115 Arg2:T100	
A10	Status T118 History_of
A11	Status T119 History_of
A12	Status T120 History_of
R120	Used_for Arg1:T119 Arg2:T118	
R121	Used_for Arg1:T120 Arg2:T118	
T110	Duration 3289 3299	los 2 años
R122	Has_Duration_or_Interval Arg1:T120 Arg2:T110	
R123	Has_Duration_or_Interval Arg1:T119 Arg2:T110	
T113	CONC 3332 3341	inclusión
#86	AnnotatorNotes T113	C1512693; Inclusion; Qualitative Concept
T167	PROC 3322 3331	selección
#90	AnnotatorNotes T167	C0242802; Patient Selection; Research Activity
R124	Before Arg1:T118 Arg2:T167	
R125	Before Arg1:T118 Arg2:T113	
T168	Neg_cue 3370 3372	no
R126	Experiences Arg1:T121 Arg2:T122	
T169	Observation 3373 3386	respondedores
#95	AnnotatorNotes T169	C0919876; Therapy responder; Finding
R127	Has_Quantifier_or_Qualifier Arg1:T121 Arg2:T169	
R128	Negation Arg1:T168 Arg2:T169	
R129	Before Arg1:T122 Arg2:T169	
R130	Experiences Arg1:T123 Arg2:T125	
R131	Experiences Arg1:T123 Arg2:T124	
R132	Experiences Arg1:T123 Arg2:T126	
T170	Observation 3497 3516	planean embarazarse
#99	AnnotatorNotes T170	C0032992; Pregnancy, Planned; Finding
T171	PHYS 3505 3516	embarazarse
#100	AnnotatorNotes T171	C0032961; Pregnancy; Organism Function
R133	Experiences Arg1:T123 Arg2:T171	
T172	Neg_cue 3530 3532	no
R134	Used_for Arg1:T129 Arg2:T128	
A13	Assertion T128 Negated
A14	Assertion T129 Negated
R135	Experiences Arg1:T127 Arg2:T128	
R136	Negation Arg1:T172 Arg2:T128	
R137	Negation Arg1:T172 Arg2:T129	
R138	Overlap Arg1:T128 Arg2:T130	
R139	Experiences Arg1:T132 Arg2:T131	
T173	Neg_cue 3629 3631	no
T174	Observation 3632 3643	disposición
A15	Assertion T174 Negated
#101	AnnotatorNotes T174	C0600109; Willing; Finding
R140	Negation Arg1:T173 Arg2:T174	
R141	Has_Quantifier_or_Qualifier Arg1:T135 Arg2:T136	
T175	Neg_cue 3778 3780	no
A16	Assertion T137 Negated
R142	Negation Arg1:T175 Arg2:T137	
R143	Has_Quantifier_or_Qualifier Arg1:T135 Arg2:T137	
T176	Quantifier_or_Qualifier 3794 3799	grave
#106	AnnotatorNotes T176	C1547227; Severe - Severity of Illness Code; Intellectual Product
R144	Has_Quantifier_or_Qualifier Arg1:T135 Arg2:T176	
T177	Observation 3951 3964	participación
#110	AnnotatorNotes T177	C1278516; Patient participation status; Finding
R145	Experiences Arg1:T140 Arg2:T135	
T141	Observation 3929 3935	riesgo
#113	AnnotatorNotes T141	C0559571; At risk - finding; Finding
R146	Overlap Arg1:T141 Arg2:T177	
R147	Experiences Arg1:T140 Arg2:T141	
R148	Before Arg1:T135 Arg2:T141	
R149	Before Arg1:T138 Arg2:T141	
R150	Causes Arg1:T143 Arg2:T142	
R151	Causes Arg1:T144 Arg2:T142	
T178	Observation 3995 3998;4031 4038	Uso alcohol
#136	AnnotatorNotes T178	C4273278; alcohol use behavior; Finding | C5428797; finding of alcohol drinking behavior; Finding
T179	Observation 3995 3998;4022 4028	Uso drogas
#137	AnnotatorNotes T179	C0524395; Habitual drug user; Finding
T180	Date 4013 4019	actual
R152	Overlap Arg1:T142 Arg2:T180	
R153	Overlap Arg1:T178 Arg2:T180	
R154	Overlap Arg1:T179 Arg2:T180	
R155	Before Arg1:T178 Arg2:T146	
R156	Before Arg1:T142 Arg2:T146	
R157	Before Arg1:T179 Arg2:T146	
R158	Overlap Arg1:T42 Arg2:T45	
T43	Result_or_Value 1487 1515	>4 g/day y persistiendo >50%
R159	Has_Result_or_Value Arg1:T42 Arg2:T43	
T44	CONC 1520 1531	valor basal
#43	AnnotatorNotes T44	C1442488; Baseline; Quantitative Concept
R160	Overlap Arg1:T42 Arg2:T46	
R161	Overlap Arg1:T45 Arg2:T46	
T147	Result_or_Value 1565 1572	<3 g/dL
R162	Has_Result_or_Value Arg1:T46 Arg2:T147	
T181	Duration 1583 1613	al menos un período de 6 meses
R163	Has_Duration_or_Interval Arg1:T46 Arg2:T181	
R164	Has_Duration_or_Interval Arg1:T42 Arg2:T181	
T182	PROC 1626 1635	selección
#44	AnnotatorNotes T182	C0242802; Patient Selection; Research Activity
R165	Before Arg1:T42 Arg2:T182	
R166	Before Arg1:T46 Arg2:T182	
T183	Duration 1676 1692	al menos 2 meses
T184	PROC 1705 1714	selección
#141	AnnotatorNotes T184	C0242802; Patient Selection; Research Activity
R167	Before Arg1:T47 Arg2:T184	
T185	Duration 1766 1794	al menos los últimos 3 meses
T186	Result_or_Value 1805 1818	< 140/90 mmHg
R168	Has_Quantifier_or_Qualifier Arg1:T48 Arg2:T52	
R169	Location_of Arg1:T51 Arg2:T48	
T49	CONC 1715 1724	inclusión
#49	AnnotatorNotes T49	C1512693; Inclusion; Qualitative Concept
R170	Before Arg1:T47 Arg2:T49	
T50	CHEM 1658 1662	ACEI
#50	AnnotatorNotes T50	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
R171	Used_for Arg1:T50 Arg2:T47	
R172	Has_Duration_or_Interval Arg1:T50 Arg2:T183	
T187	CHEM 1668 1671	ARB
#52	AnnotatorNotes T187	C0815017; Angiotensin Receptor Antagonists; Pharmacologic Substance
R173	Has_Duration_or_Interval Arg1:T187 Arg2:T183	
R174	Used_for Arg1:T187 Arg2:T47	
R175	Has_Duration_or_Interval Arg1:T48 Arg2:T185	
R176	Has_Result_or_Value Arg1:T48 Arg2:T186	
A17	Status T122 History_of
R177	Before Arg1:T170 Arg2:T171	
#147	AnnotatorNotes T154	C3890404; Clinical Trial Subject Information Form; Intellectual Product (?)
#157	AnnotatorNotes T180	C0521116; Current (present time); Temporal Concept
A18	Experiencer T20 Patient
A19	Experiencer T21 Patient
A20	Experiencer T22 Patient
A21	Experiencer T30 Patient
A22	Experiencer T57 Patient
A23	Experiencer T89 Patient
A24	Experiencer T121 Patient
A25	Experiencer T123 Patient
A26	Experiencer T127 Patient
A27	Experiencer T132 Patient
A28	Experiencer T133 Other
A29	Experiencer T139 Other
A30	Experiencer T145 Other
A31	Experiencer T140 Patient
A32	Status T171 Future
